MONTRÉAL, Aug. 2, 2017 /CNW Telbec/ - In the wake of Clementia Pharmaceuticals' initial public offering (IPO), the Fonds de solidarité FTQ confirms it has invested US$ 10 million in the company in March 2017. The Fonds is also participating in the company's IPO. Clementia Pharmaceuticals is developing a drug to treat fibrodysplasia ossificans progressiva, an ultra-rare and severely debilitating disorder.
"By supporting Clementia Pharmaceuticals, the Fonds is once again demonstrating its commitment to the life sciences sector. However, it also reflects the potential of the biotech industry in Québec. A long-time investor in this sector, the Fonds targeted the life sciences sector as one of its priority areas of investment following its strategic planning exercise."Gaétan Morin, President and Chief Executive Officer, Fonds de solidarité FTQ
"Due to a plethora of seasoned drug development experts and research and services infrastructure, Québec is poised to be a global leader in the development of novel therapies. Clementia Pharmaceuticals is a recent example of this potential. We would like to thank the Clementia management team, including Clarissa Desjardins, President and CEO and Michael Singer, CFO as well as the company's investors, Orbimed, NEA and particularly BDC Capital who played a major role in the company's creation."Alain Denis, Senior Vice-President for Innovation, Fonds de solidarité FTQ
"Besides Clementia's IPO, the $US 68 million in financing recently closed by Repare Therapeutics and Zymeworks' successful IPO is indicative of Quebec's and Canada's biotech ecosystem regaining its past glory. Through investments in specialized funds such as Versant Ventures VI and direct investments the Fonds is positioning itself as a key player in this renewal."Didier Leconte, Senior Investment Director for Life Sciences, Fonds de solidarité FTQ
About the Fonds de solidarité FTQThe Fonds de solidarité FTQ is a development capital investment fund that channels the savings of Quebecers into investments. As at May 31, 2017, the organization had $13.1 billion in net assets, and through its current portfolio of investments has helped create and protect 186,440 jobs. The Fonds is a partner in more than 2,700 companies and has 645,664 shareholder-savers. Please visit fondsftq.com for more information.
SOURCE Fonds de solidarité FTQ
Subscribe to our Free Newsletters!
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...View All